A compliance department of a large pharmaceutical company and have been receiving a lot of questions lately about the company's use of social media to promote its products.

Address the two questions below in a 3-5 pp. memo to your marketing and advertising team.

1. Can we use Twitter for product promotion of our hypertension drug Sinexa (which does not have a black box warning) and, if so, what guidelines should we follow?

2. We found a third-party blog, not affiliated with our company, in which the author discusses Sinexa. In one place, the author makes a favorable comment about Sinexa's off-label use for sinus infections, and in another place, he lists a risk that is not accurate and is not a part of the product labeling.

Can we correct just the statement about the inaccurate risk? How should we go about correcting this incorrect information?